Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): A cluster-randomised controlled trial

The Lancet

Volumn 380, Issue 9855, 2012, Pages 1741-1748

  Simmons, Rebecca K ^a   Echouffo Tcheugui, Justin B ^a   Sharp, Stephen J ^a   Sargeant, Lincoln A ^a   Williams, Kate M ^b   Prevost, A Toby ^b,c   Kinmonth, Ann Louise ^b   Wareham, Nicholas J ^a   Griffin, Simon J ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH PROGRAM; HEALTH SURVEY; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCREENING;

EID: 84869094223     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61422-6     Document Type: Article

References (39)

1. Simmons RK, Echouffo-Tcheugui JB, Griffin SJ. Screening for type 2 diabetes: an update of the evidence. Diabetes Obes Metab 2010; 12: 838-44.
2. Department of Health. Putting prevention first. Vascular checks: risk assessment and management. London: Department of Health, 2008.
3. Echouffo-Tcheugui JB, Simmons RK, Williams KM, et al. The ADDITION-Cambridge trial protocol: a cluster-randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients. BMC Public Health 2009; 9: 136.
4. Eborall HC, Griffin SJ, Prevost AT, Kinmonth AL, French DP, Sutton S. Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 2007; 335: 486.
5. Paddison CA, Eborall HC, Sutton S, et al. Are people with negative diabetes screening tests falsely reassured? Parallel group cohort study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 2009; 339: b4535.
6. Autier P, Boniol M, Gavin A, Vatten LJ. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ 2011; 343: d4411.
7. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-28.
8. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385-94.
9. Uusitupa M, Peltonen M, Lindstrom J, et al. Ten-year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study - secondary analysis of the randomized trial. PLoS One 2009; 4: e5656.
10. Kuo HS, Chang HJ, Chou P, Teng L, Chen TH. A Markov chain model to assess the efficacy of screening for non-insulin dependent diabetes mellitus (NIDDM). Int J Epidemiol 1999; 28: 233-40.
11. Chang HJ, Kuo HS, Tung TH, Chou P, Chen TH. Evaluation of a population-based screening for type 2 diabetes: a community-based screening project in Puli, Taiwan. Prev Med 2000; 31: 396-402.
12. Kahn R, Alperin P, Eddy D, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 2010; 375: 1365-74.
13. Sargeant LA, Simmons RK, Barling RS, et al. Who attends a UK diabetes screening programme? Findings from the ADDITION-Cambridge study. Diabet Med 2010; 27: 995-1003.
14. Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ. Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. Diabetes Metab Res Rev 2000; 16: 164-71.
15. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications; Part 1: diagnosis and classification of diabetes mellitus. Switzerland: World Health Organisation, 1999.
16. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.
17. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-59.
18. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
19. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13.
20. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diab Care 1997; 20: 614-20.
21. McIntosh A, Hutchinson A, Home PD, et al. Clinical guidelines and evidence review for type 2 diabetes: management of blood glucose. Sheffield: University of Sheffield, 2001.
22. Huber PJ. The behavior of maximum likelihood estimates under nonstandard conditions. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability; 1967; Berkeley, CA: University of California Press; 1967: 221-33.
23. Hain D. Briefing 18. The index of multiple deprivation. Cambridge: Eastern Region Public Health Observatory, 2007.
24. Simmons RK, Rahman M, Jakes RW, et al. Effect of population screening for type 2 diabetes on mortality: long-term follow-up of the Ely cohort. Diabetologia 2011; 54: 312-19.
25. Vernon SW. Participation in colorectal cancer screening: a review. J Natl Cancer Inst 1997; 89: 1406-22.
26. Diabetes United Kingdom. Early identification of people with type 2 diabetes. Position statement, September 2008. http://www.diabetes.org.uk (accessed Sept 16, 2012).
27. Waugh N, Scotland G, McNamee P, et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess 2007; 11: iii-iv, ix-xi, 1-125.
28. Campbell SM, Roland MO, Middleton E, Reeves D. Improvements in quality of clinical care in English general practice 1998-2003: longitudinal observational study. BMJ 2005; 331: 1121.
29. Doran T, Fullwood C, Gravelle H, et al. Pay-for-performance programs in family practices in the United Kingdom. N Engl J Med 2006; 355: 375-84.
30. Spijkerman A, Griffin S, Dekker J, Nijpels G, Wareham NJ. What is the risk of mortality for people who are screen positive in a diabetes screening programme but who do not have diabetes on biochemical testing? Diabetes screening programmes from a public health perspective. J Med Screen 2002; 9: 187-90.
31. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89.
32. Griffin SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011; 378: 156-67.
33. Rahman M, Simmons RK, Hennings SH, Wareham NJ, Griffin SJ. How much does screening bring forward the diagnosis of type 2 diabetes and reduce complications? Twelve year follow-up of the Ely cohort. Diabetologia 2012; 55: 1651-59.
34. Thomason MJ, Biddulph JP, Cull CA, Holman RR. Reporting of diabetes on death certificates using data from the UK Prospective Diabetes Study. Diabet Med 2005; 22: 1031-36.
35. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44 (suppl 2): S14-21.
36. Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 2004; 109: 1101-07.
37. ERPHO. http://www.erpho.org.uk/ (accessed Sept 16, 2012).
38. Hennekens CH, Buring JE. Epidemiology in medicine. Philadelphia: Lippincott, Williams & Wilkins, 1987.
39. Marteau TM, Mann E, Prevost AT, et al. Impact of an informed choice invitation on uptake of screening for diabetes in primary care (DICISION): randomised trial. BMJ 2010; 340: c2138.